Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
MORE►
Lantern Pharma Inc.
Lantern Pharma CEO Panna Sharma [Courtesy: Lantern Pharma]
Lantern Pharma’s New Drug Candidate for Mantle Cell Lymphoma Shows Promise
by Quincy Preston | Dec 22, 2022
The Dallas-based biopharmaceutical company expects to begin testing the drug candidate in a “first in human” trial in mid-2023. The drug was developed using the publicly traded company’s AI/ML drug development platform.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
Lantern, in collaboration with the National Cancer Institute, recently published insights on how AI can be used to find new indications for cancer drugs in record times with significant reductions in costs.
by Alex Edwards |
Nov 18, 2020
Lantern Pharma amassed 1 billion data points on its proprietary artificial intelligence platform, which it believes is the most of any company in biotech. Now, the company is able to reduce cost, time, and risk to establish a more sustainable route in oncology drug development.
MORE►
by Amy Wolff Sorter |
May 5, 2017
Dallas-based Lantern Pharma is a clinical stage biotech company pioneering in the field of precision oncology.
MORE►
